About Magellan Diagnostics
Magellan Diagnostics is a company based in Billerica (United States) founded in 1968 was acquired by Meridian Bioscience in March 2016.. Magellan Diagnostics has raised $34 million across 3 funding rounds from investors including Meridian Bioscience, NIH and Abingworth. Magellan Diagnostics offers products and services including LeadCare II, LeadCare Plus, LeadCare Ultra, and Analytical Services. Magellan Diagnostics operates in a competitive market with competitors including Baseline Health, Oligoscan, Beaufort Bar and ToxTest, among others.
- Headquarter Billerica, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Meridian Bioscience, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$34 M (USD)
in 3 rounds
-
Latest Funding Round
$16 M (USD), Debt – Conventional
Nov 29, 2006
-
Investors
Meridian Bioscience
& 9 more
-
Employee Count
Employee Count
-
Acquired by
Meridian Bioscience
(Mar 24, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Magellan Diagnostics
Magellan Diagnostics offers a comprehensive portfolio of products and services, including LeadCare II, LeadCare Plus, LeadCare Ultra, and Analytical Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
CLIA-waived device for quick lead exposure detection in practices.
Solution for labs with smaller testing volumes and control features.
High-throughput system for convenient lead testing in high-volume settings.
Support for lead analysis and reporting to aid health risk management.
Funding Insights of Magellan Diagnostics
Magellan Diagnostics has successfully raised a total of $34M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $16 million completed in November 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Debt – Conventional — $16.0M
- First Round First Round
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2006 | Amount | Series C - Magellan Diagnostics | Valuation |
investors |
|
| Nov, 2006 | Amount | Debt – Conventional - Magellan Diagnostics | Valuation |
investors |
|
| Mar, 2005 | Amount | Grant - Magellan Diagnostics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Magellan Diagnostics
Magellan Diagnostics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Meridian Bioscience, NIH and Abingworth. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Ampersand Capital Partners is focused on investments in healthcare and life sciences.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Magellan Diagnostics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Magellan Diagnostics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Magellan Diagnostics Comparisons
Competitors of Magellan Diagnostics
Magellan Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Baseline Health, Oligoscan, Beaufort Bar and ToxTest, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Develops test kits for diagnosing body toxins to promote health monitoring.
|
|
| domain | founded_year | HQ Location |
Develops innovative diagnostic devices for screening physiological imbalances.
|
|
| domain | founded_year | HQ Location |
Provides diagnostic tests for detecting lead poisoning to ensure public health safety.
|
|
| domain | founded_year | HQ Location |
Offers DIY urine tests for detecting 11 heavy metals in the body.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Magellan Diagnostics
Frequently Asked Questions about Magellan Diagnostics
When was Magellan Diagnostics founded?
Magellan Diagnostics was founded in 1968 and raised its 1st funding round 37 years after it was founded.
Where is Magellan Diagnostics located?
Magellan Diagnostics is headquartered in Billerica, United States. It is registered at Billerica, Massachusetts, United States.
Is Magellan Diagnostics a funded company?
Magellan Diagnostics is a funded company, having raised a total of $34M across 3 funding rounds to date.
What does Magellan Diagnostics do?
Magellan Diagnostics develops point-of-care diagnostic platforms for heavy metal toxicity. The company was formerly known as ESA, Inc. and was founded by four PhD graduates from the Massachusetts Institute of Technology. It has three microfluidics-based platforms for lead testing at the point-of-care. The bench top analyzer for the measurement of lead in blood is based on Anodic Stripping Voltammetry (ASV). In addition, it also provides heavy metal toxicity testing services via its reference laboratory.
Who are the top competitors of Magellan Diagnostics?
Magellan Diagnostics's top competitors include Baseline Health, Oligoscan and Beaufort Bar.
What products or services does Magellan Diagnostics offer?
Magellan Diagnostics offers LeadCare II, LeadCare Plus, LeadCare Ultra, and Analytical Services.
Who are Magellan Diagnostics's investors?
Magellan Diagnostics has 10 investors. Key investors include Meridian Bioscience, NIH, Abingworth, Tekla Capital Management, and NewStar Financial.